Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There in lies the problem... he shouldn’t comment on it if you don’t know it’s history
It’s been my experience that they are resolute in their “protocol”.
With the drug leron he might be... not his career.
... but that was the fear .. that the FDA will drag this out longer.
He’s inexperienced, not the drug.
Covid hype dying down... market is moving on. Thanks for the hype VYST.
Lol, yep. “Maybe 2021 we’ll see... thanks for the data”
I’m sure they are discussing results with FDA to make the next PR a little more powerful than just results.
Not instead, in addition to.
That’s the government for ya. They will assign value even if you paid nothing.
Robinhooders are desperate for a Covid cure play. Look at kodk... that was based on HCQ.
Whoever gets to Naz first will get the lions share of fomo money.
Could go beyond $30 easy with msm spin... approval would pop it to $60. I know I’ve got robinhood money waiting on hgen to get to the Naz
Keep the loading zone open...
Mud slinging... just like poker... doesn’t matter until the chips move.
Yeah, that is why leron is a little better for M2M on out patient basis, especially for long haulers.
Nice power point today...
Too bad leron may not make it to market for Covid. Any idea why lenz couldn’t be SubQ? They’re both MABs...
Thanks for the welcome message. I’ll do more DD on GM-CSF. Can lenizilumab be administered via SubQ? Just curious.
Nader is less about science and more about the street game. His background isn’t medical so he focuses on business and strategy. Problem is he plays a zero sum game and the 3 arm was his countermove to the combo.
HGEN changing the endpoints of the P3 trial was smart as the SOC has gotten better. It’s less about mortality then it used to be... and that numbers game may make the lenz trials more successful than leron.
Nader is too stubborn to change the endpoints (note he ridiculed Gilead for doing that). It’s a smart move by HGEN for sure.
There are many reasons why I think HGEN will outperform CYDY in terms of time to market.
Compare notes with Sykes
Bingo... and conversely Rantes is elevated in only about half of patients.
Need a broad spectrum immunomodulator to “cover” the population.
I don’t keep a log of my DD, but it’s all out there in leron trial history. Pro140 has been around a long time. Look for a Covid compilation in a few new publications by Inceldx and CytoDyn.
Otherwise it’s digging through hospital clinical data.
Not in the OTC, maybe big boards
Came from Gilead. Cydy got arrogant and asked for a 3 arm trial instead to prove leron was the better choice. Gilead wisely turned that down.
Hgen benefits from it... hence my hedge
Yep. I’ll bet both ponies as they have their own pros/cons... but I’m realizing the HGEN has a better jockey.
They didn’t at first... cydy unwisely declined the combo offer
Market cap is based on SS...
Based on EINDs, trials.
The Hype is just hype
Share structure won’t support a dollar yet, but in 5 years yes.
Yeah, it doesn’t matter really... Lenz MOA is good and much more effective than current SOC. So if they get through P3 and to Naz it’ll look amazing. Combo that with Remmy and it’ll be the new SOC. CytoDyn unwisely turned down the combo offer awhile back.
It’s a marketing race now since there’s an unmet need for Covid. I’ll ride both but they both share very similar markets. The SS and inst ownership of HGEN is much better.
Look at NASA vs SpaceX... nuff said. Private sector has to deliver ingenuity.
Yeah, I slapped the ask at $5 for fun
He’s overconfident and arrogant. Making too mistakes in the BP world. I’m sliding toward HGEN in first to market. CytoDyn has the better drug but HGEN has better leadership.
I’d pick up some HGEN stock, they’ll be on Naz first and they are playing with BP better. CytoDyn has a better drug but it appears NP is not playing ball with BP.
Hgen will likely get to market first with better seasoned leadership. Lower float and higher institutional ownership. Robinhooders will blow that up.
CD10 data will be good but useless with NP tactics.
Great job NP, lol. He’s trying to stay above $4 for Naz application.
He’s now said M2M top line results next week. As the week slides buy the stock will drop.
Short attack every day I’ll bet.
Fake support at $4.90 lol
IMO the only way to get funding now is through an OZ and since Chas has a side company that specializes in OZs I’m sure that’s what he’s doing. Note: I’ve not talked with Chas... this is just My DD.
The move should be Easy and quick since they don’t have much.
Clock is ticking on the funding because if the Democrats win the AMERICAN election OZs will likely disappear. Chas needs to move fast and lock it in. Hence my recent urgency.
BUT that should also expedite the funding process itself... rich people burying money trying to hide from higher democrat taxes.
He’s a pumper for sure.... buy buy buy. He’s got some nice Indian jewelry for ya as well. He’ll give ya a deal.
Gotta get to Naz before $25. Need the Robinhooders to fomo.
Lol, that’s VYST hype for ya. Smells like Greg. Nice PPs boost though. He’s getting better at it
Agreed that we should diversify but it seems like it’s all hinging on FDA.
S2C is stalling and FDA could ask for p3 M2M.
They could easily bleed out cydy and lock them out. Meanwhile lesser drugs get $$ and approval.
Gotta get NP out of the negotiating room
NP has bigger people to piss off.
Is it me or does it seem like the twitter account reacts to a market drop? Which is fine but don’t be super obvious there guys.
Agreed on that... let’s see if the hype can gain them market share.
When do the patents expire? Hmmm...